ThePeptideGuide.uk LogoNavigation

Educational purposes only. Not medical advice. Consult healthcare professionals before use.

Healing & Recovery
Phase 3

Brilacidin

Brilacidin

Also known as: PMX-30063, Defensin Mimetic, Host Defense Peptide Mimetic

Overview

Key Facts

Primary Goal: A synthetic small-molecule mimetic of human host defense peptides (defensins)

A synthetic small-molecule mimetic of human host defense peptides (defensins). Designed to replicate the antimicrobial and immunomodulatory functions of natural defensins while offering improved stability and pharmacokinetics over native peptides. Half-Life ~8 hours Typical Dose 0.6–1.2 mg Frequency 1x daily Cycle Length 7-14 days (acute infection), longer for chronic use

Dosing Information

Half-Life

~8 hours

Typical Dose

0.6–1.2 mg

Frequency

1x daily

Cycle Length

7-14 days (acute infection), longer for chronic use

Administration Routes:

oraltopicalintravenous

Storage & Reconstitution

Unreconstituted (Powder)

Temperature2–8°C (36–46°F)
DurationUp to 3 months

Reconstituted (Mixed)

Temperature2–8°C (36–46°F)
Duration2-4 weeks

Research Summary

Phase 3

Developed by Innovation Pharmaceuticals (formerly Cellceutix). Completed Phase 2 clinical trials for acute bacterial skin and skin structure infections (ABSSSI) with positive results. Also studied for oral mucositis and inflammatory bowel disease. Investigated as potential COVID-19 therapeutic. Represents a novel class of non-peptide immune defense mimetics.

Frequently Asked Questions

Common questions about Brilacidin

UK-Specific Information

Exclusive data points and guidance for UK residents using Brilacidin

UK Lab Testing

US Lab Testing

Recommended labs: Quest Diagnostics, LabCorp ($120-$200 for peptide safety panel)

Why this matters: UK-specific lab testing guidance not available on US competitor sites

Commonly Stacked With